Premium
Studies on neutralization of L‐asparaginase activity in vitro and in vivo
Author(s) -
Vadlamudi Srikrishna,
Padarathsingh Martin,
Bonmassar Enzo,
Waravdekar Vaman,
Goldin Abraham
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197106)27:6<1321::aid-cncr2820270607>3.0.co;2-y
Subject(s) - in vivo , asparaginase , drug , in vitro , cyclophosphamide , medicine , pharmacology , antibody , precipitin , chemotherapy , immunology , leukemia , biology , biochemistry , lymphoblastic leukemia , microbiology and biotechnology
L‐asparaginase was effective in increasing the life span of leukemic (L5178Y) mice. However, the therapeutic effect of the drug was reduced when this treatment was preceded by a series of pretreatments (relative to tumor implantation) with the drug. The data from in vitro and in vivo studies revealed the involvement of humoral antibodies to L‐asparaginase in reducing therapeutic activity of the drug in leukemic mice. Similarly, the antileukemic activity of the drug was neutralized when L‐asparaginase was pre‐incubated with immune sera obtained from rabbits or mice. The therapeutic activity of the drug was retained when the pretreatment with L‐asparaginase in mice was accompanied by a single injection of cyclophosphamide, an immunosuppressant drug. Sera from these mice did not contain precipitin antibody to L‐asparaginase.